GO:0035255 ionotropic glutamate receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035255 (ionotropic glutamate receptor binding) is a molecular function describing the selective binding of a protein or ligand to ionotropic glutamate receptors (iGluRs), which are ligand-gated ion channels.
• iGluR binding is governed by the ligand-binding domain (LBD), where glutamate and glycine bind with specific energetics and conformational changes [1,2,4].
• Constitutive activity can arise from hydrophobic substitutions in the LBD, altering receptor gating independent of ligand.
• Mutations in iGluR genes are linked to neurologic and psychiatric diseases, including schizophrenia and epilepsy [7,8].
• Studying GO:0035255 requires integrated methods: binding assays, electrophysiology, structural biology, and CRISPR-based models [3,5].
• EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, and library screening services to dissect iGluR binding mechanisms.
Description
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate fast excitatory synaptic transmission in the mammalian central nervous system. The molecular function GO:0035255, ionotropic glutamate receptor binding, refers to the binding of a molecule (e.g., glutamate, glycine, or a protein) to these receptors, a critical step for channel activation and signal transduction. This binding event is highly specific and involves conformational changes in the ligand-binding domain (LBD) that couple ligand recognition to ion channel opening [1,2]. Understanding this function is essential for neurobiology, as iGluRs are central to synaptic plasticity, learning, and memory, and their dysfunction is implicated in numerous neurological and psychiatric disorders [7,8]. Researchers study GO:0035255 to uncover the molecular basis of receptor activation, to develop pharmacological tools, and to model disease-associated mutations [3,5].
ionotropic glutamate receptor binding At A Glance
| GO ID | GO:0035255 |
|---|---|
| GO term | ionotropic glutamate receptor binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to ionotropic glutamate receptors, which are ligand-gated ion channels that mediate fast excitatory neurotransmission. |
| Ligand specificity | Glutamate, glycine, and synthetic agonists/antagonists bind to the ligand-binding domain [2,3,4]. |
| Structural basis | Ligand-binding domain (LBD) undergoes conformational changes upon binding, leading to channel activation [1,5]. |
| Disease relevance | Mutations in iGluR genes are associated with neurologic and psychiatric disorders [7,8]. |
| Research methods | Binding assays, electrophysiology, X-ray crystallography, cryo-EM, and CRISPR-based gene editing [3,5]. |
What Is GO:0035255?
GO:0035255 (ionotropic glutamate receptor binding) is defined as the binding to an ionotropic glutamate receptor. Ionotropic glutamate receptors are ligand-gated ion channels that bind glutamate and exert their effects through the regulation of ion channels. This function encompasses the interaction of glutamate, glycine, or other ligands with the receptor's ligand-binding domain, as well as the binding of auxiliary proteins that modulate receptor function [4,5].
Why Is ionotropic glutamate receptor binding Important in Cell Biology?
GO:0035255 is fundamental to understanding how ionotropic glutamate receptors translate chemical signals into electrical activity in the brain. This binding event is the first step in fast excitatory neurotransmission, and its dysregulation is linked to a wide range of neurological and psychiatric conditions, including schizophrenia, epilepsy, and neurodegenerative diseases [7,8]. Moreover, the binding function is a major target for therapeutic drugs, such as quinoxalinediones, which act as antagonists. Studying this function helps elucidate the molecular mechanisms of synaptic plasticity and provides a basis for developing treatments for glutamate-related disorders.
• Mediates fast excitatory synaptic transmission in the central nervous system.
• Underlies synaptic plasticity, learning, and memory.
• Dysfunction is implicated in schizophrenia, as shown by altered iGluR binding in thalamic nuclei.
• Mutations in iGluR genes cause human neurologic diseases, including epilepsy and intellectual disability.
• Serves as a target for pharmacological agents like quinoxalinediones.
• Constitutive activity via LBD substitutions highlights the importance of binding for receptor gating.
• Provides a model system for studying ligand-gated ion channel energetics.
• Enables structural biology studies of ligand recognition and allostery [1,4].
• Facilitates development of CRISPR models to test disease-associated mutations.
• Informs drug discovery for neuropsychiatric disorders.
What Happens During ionotropic glutamate receptor binding?
Ligand recognition and binding
In simple terms: Glutamate or similar molecules fit into a specific pocket on the receptor, like a key in a lock.
The ligand-binding domain (LBD) of ionotropic glutamate receptors contains a cleft that selectively binds glutamate, glycine, or other agonists. Binding is driven by electrostatic and hydrophobic interactions, and the energetics of glutamate binding have been characterized using molecular dynamics simulations. The LBD undergoes a conformational change from an open to a closed state upon ligand binding, which is a critical step for receptor activation.
Conformational change and channel gating
In simple terms: When the ligand binds, the receptor changes shape, opening a channel for ions to flow.
Ligand binding induces closure of the LBD, which is transmitted to the transmembrane domain, leading to opening of the ion channel pore. This coupling involves a series of conformational rearrangements, as revealed by enhanced sampling simulations and structural studies [1,5]. The efficiency of this coupling can be altered by mutations, such as hydrophobic substitutions in the LBD that cause constitutive activity.
Ion flux and signal transduction
In simple terms: Ions rush through the open channel, changing the electrical state of the neuron.
Once the channel opens, sodium, potassium, and calcium ions flow across the membrane, depolarizing the postsynaptic cell and initiating downstream signaling cascades. The ion flux is regulated by the duration and frequency of ligand binding, as well as by auxiliary proteins that modulate receptor trafficking and gating.
Desensitization and receptor recycling
In simple terms: After signaling, the receptor closes and may be internalized to reset the system.
Prolonged exposure to glutamate leads to desensitization, a process where the receptor adopts a closed state even with ligand bound. This involves conformational changes in the LBD and is modulated by subunit composition. Desensitized receptors can be internalized and recycled, affecting synaptic strength.
Key Genes Involved in GO:0035255 ionotropic glutamate receptor binding
The following genes encode subunits and auxiliary proteins of ionotropic glutamate receptors that directly participate in or modulate GO:0035255.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRIA1 | AMPA receptor subunit GluA1; binds glutamate and forms cation channels | Mediates fast excitatory transmission; target for epilepsy and schizophrenia studies [6,8] |
| GRIA2 | AMPA receptor subunit GluA2; controls calcium permeability | Critical for synaptic plasticity; mutations linked to neurologic disorders |
| GRIA3 | AMPA receptor subunit GluA3 | Modulates receptor assembly and trafficking |
| GRIA4 | AMPA receptor subunit GluA4 | Expressed in specific brain regions; involved in development |
| GRIN1 | NMDA receptor subunit GluN1; binds glycine | Essential for NMDA receptor function; mutations cause neurodevelopmental disorders [4,7] |
| GRIN2A | NMDA receptor subunit GluN2A; binds glutamate | Implicated in epilepsy and intellectual disability |
| GRIN2B | NMDA receptor subunit GluN2B; binds glutamate | Associated with schizophrenia and autism [7,8] |
| GRIN2C | NMDA receptor subunit GluN2C | Modulates receptor properties in cerebellum |
| GRIN2D | NMDA receptor subunit GluN2D | Contributes to NMDA receptor diversity |
| GRIN3A | NMDA receptor subunit GluN3A; binds glycine | Regulates receptor trafficking and calcium permeability |
| GRIN3B | NMDA receptor subunit GluN3B | Modulates NMDA receptor function in motor neurons |
| GRIK1 | Kainate receptor subunit GluK1 | Mediates kainate-induced currents; involved in epilepsy |
| GRIK2 | Kainate receptor subunit GluK2 | Forms functional kainate receptors; linked to schizophrenia |
| GRIK3 | Kainate receptor subunit GluK3 | Modulates synaptic transmission |
| GRIK4 | Kainate receptor subunit GluK4 | High-affinity kainate receptor; associated with bipolar disorder |
| GRIK5 | Kainate receptor subunit GluK5 | Modulates receptor assembly |
| GRID1 | Delta-1 receptor subunit; orphan iGluR | May modulate AMPA receptor trafficking |
| GRID2 | Delta-2 receptor subunit; orphan iGluR | Involved in cerebellar plasticity; mutations cause ataxia |
How Is ionotropic glutamate receptor binding Regulated?
The binding function of ionotropic glutamate receptors is regulated at multiple levels. Allosteric modulators can bind to sites outside the LBD and influence receptor activity. Phosphorylation of intracellular domains by kinases such as PKC and CaMKII modulates receptor trafficking and gating. Auxiliary subunits (e.g., TARPs, CNIHs) can alter ligand-binding affinity and channel properties. Additionally, alternative splicing and RNA editing (e.g., Q/R editing in GRIA2) change the functional properties of the receptor. These regulatory mechanisms ensure precise control of synaptic transmission.
ionotropic glutamate receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRIN2A | Epilepsy, intellectual disability | Knock-in mouse with patient mutation; CRISPR point mutation in neurons |
| GRIA2 | Schizophrenia, epilepsy | Knockout and point-mutation cell lines; electrophysiology [7,8] |
| GRIN2B | Schizophrenia, autism | Overexpression and knockout models; binding assays [7,8] |
| GRIK2 | Schizophrenia, bipolar disorder | CRISPR knockout in iPSC-derived neurons |
| GRID2 | Cerebellar ataxia | Knock-in mouse; point mutation of ligand-binding domain |
Schizophrenia
Altered ionotropic glutamate receptor binding has been observed in thalamic nuclei of schizophrenia patients, suggesting a role for glutamatergic dysfunction in the disease. Postmortem studies show changes in receptor binding and subunit mRNA expression, which may contribute to cognitive deficits.
Epilepsy and neurodevelopmental disorders
Mutations in iGluR genes, such as GRIN2A and GRIA2, are associated with epilepsy, intellectual disability, and developmental delay. These mutations often affect ligand-binding affinity or channel gating, leading to aberrant neuronal excitability.
Neurodegenerative diseases
Excessive glutamate receptor activation (excitotoxicity) contributes to neuronal death in conditions like Alzheimer's disease and amyotrophic lateral sclerosis. Targeting iGluR binding is a therapeutic strategy for neuroprotection.
From ionotropic glutamate receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a mutation alter ligand-binding affinity? | Point-mutation knock-in cell line; binding assays [3,5] |
| What is the effect of gene knockout on receptor function? | CRISPR knockout in neuronal cell lines or primary neurons |
| How does a disease-associated mutation affect channel gating? | Knock-in mouse model or iPSC-derived neurons |
| Can a protein tag reveal receptor localization? | Tagged knock-in (e.g., GFP) for imaging |
| Does overexpression of a subunit change synaptic transmission? | Overexpression in cultured neurons; electrophysiology |
| What genes modulate iGluR binding? | CRISPR library screening in neuronal cells |
How to Study the ionotropic glutamate receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and density of iGluRs | Quantifying receptor binding in brain tissue [3,8] |
| Patch-clamp electrophysiology | Ion channel currents | Functional characterization of receptor gating [5,6] |
| X-ray crystallography | 3D structure of ligand-binding domain | Visualizing ligand-receptor interactions [1,4] |
| Cryo-EM | Structure of full-length receptor | Understanding conformational changes |
| Molecular dynamics simulations | Binding energetics and dynamics | Computational analysis of ligand binding |
| CRISPR knockout | Loss-of-function phenotype | Determining gene necessity in receptor function |
| CRISPR point mutation | Effect of specific amino acid change | Modeling disease-associated mutations [5,7] |
| CRISPR knock-in | Tagged or mutant receptor expression | Tracking receptor localization and function |
Binding assays
Radioligand binding assays using tritiated glutamate or antagonists measure affinity and receptor density in membrane preparations [3,8]. These assays are essential for quantifying GO:0035255 activity and screening for modulators.
Electrophysiology
Patch-clamp recordings measure ion channel currents in response to ligand application, providing functional readouts of receptor activation and desensitization [5,6]. This method directly links binding to channel gating.
Structural biology
X-ray crystallography and cryo-electron microscopy resolve the three-dimensional structures of the ligand-binding domain in apo and ligand-bound states, revealing conformational changes [1,4]. Molecular dynamics simulations complement these studies by exploring binding energetics.
CRISPR-based genetic models
CRISPR/Cas9 knockout, point mutation, and knock-in models allow precise manipulation of iGluR genes to study their role in binding and disease [5,7]. These models can be combined with functional assays to dissect mechanisms.
How CRISPR Can Be Used to Study GO:0035255 ionotropic glutamate receptor binding
Knockout
CRISPR knockout of iGluR genes (e.g., GRIA1, GRIN1) in cell lines or primary neurons abolishes receptor expression, allowing researchers to study the loss of binding function and its downstream effects on synaptic transmission.
Point Mutation
Introducing specific point mutations (e.g., in the ligand-binding domain) via CRISPR base editing or HDR enables precise modeling of disease-associated variants and analysis of their impact on binding affinity and channel gating [5,7].
Knock-in
Knock-in of tagged receptors (e.g., GFP-tagged GluA1) or disease mutations allows visualization and functional analysis of receptors in their native context, providing insights into trafficking and binding dynamics.
Overexpression
Overexpression of wild-type or mutant iGluR subunits in heterologous cells or neurons can enhance receptor binding signals and facilitate biochemical and electrophysiological studies.
How EDITGENE Supports ionotropic glutamate receptor binding Research
Researchers studying ionotropic glutamate receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, synaptic transmission, or disease. EDITGENE provides a comprehensive suite of CRISPR services to create precise genetic models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for ionotropic glutamate receptor binding research.
Frequently Asked Questions About ionotropic glutamate receptor binding
What is GO:0035255?
GO:0035255 is the Gene Ontology molecular function term for ionotropic glutamate receptor binding, which describes the binding to ionotropic glutamate receptors, ligand-gated ion channels that mediate fast excitatory neurotransmission.
What genes are involved in ionotropic glutamate receptor binding?
Genes encoding iGluR subunits include GRIA1-4 (AMPA), GRIN1, GRIN2A-D, GRIN3A-B (NMDA), GRIK1-5 (kainate), and GRID1-2 (delta) [6,7].
How does glutamate bind to its receptor?
Glutamate binds to the ligand-binding domain of iGluRs, inducing a conformational change that opens the ion channel. The binding energetics have been characterized by simulations and structural studies [1,2,4].
What diseases are associated with ionotropic glutamate receptor binding?
Altered binding is linked to schizophrenia, epilepsy, intellectual disability, and neurodegenerative diseases [7,8].
What methods are used to study ionotropic glutamate receptor binding?
Common methods include radioligand binding assays, patch-clamp electrophysiology, X-ray crystallography, cryo-EM, and CRISPR-based genetic models [3,5,6].
Can CRISPR be used to study ionotropic glutamate receptor binding?
Yes, CRISPR knockout, point mutation, and knock-in models allow precise manipulation of iGluR genes to study binding mechanisms and disease mutations [5,7].
What is the role of the ligand-binding domain in iGluRs?
The ligand-binding domain (LBD) is responsible for recognizing and binding glutamate or glycine, and its conformational changes trigger channel opening [1,4].
How does constitutive activity of iGluRs occur?
Constitutive activity can arise from hydrophobic substitutions in the LBD that mimic the ligand-bound state, leading to channel opening without ligand.
What is the significance of quinoxalinedione binding to iGluRs?
Quinoxalinediones are antagonists that bind to the LBD; their deprotonation is important for receptor binding, as studied in pharmacological research.
How does EDITGENE support iGluR research?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to facilitate mechanistic and disease studies on iGluR binding.
Conclusion
GO:0035255 (ionotropic glutamate receptor binding) is a central molecular function in neurobiology, underpinning fast excitatory synaptic transmission and implicated in numerous neurological and psychiatric disorders. Understanding the structural and energetic basis of ligand binding, as well as the regulatory mechanisms, is crucial for developing targeted therapies. CRISPR-based models and advanced biochemical assays continue to unravel the complexities of iGluR function, offering hope for novel treatments.
References
- 1. Lau AY. 2019. Enhanced sampling of glutamate receptor ligand-binding domains.. Neurosci Lett 700:17-21 PMID: 29665428
- 2. Yu A et al.. 2017. Energetics of Glutamate Binding to an Ionotropic Glutamate Receptor.. J Phys Chem B 121(46):10436-10442 PMID: 29065265
- 3. Dudić A et al.. 2019. Quinoxalinedione deprotonation is important for glutamate receptor binding.. Biol Chem 400(7):927-938 PMID: 30903748
- 4. Yu A et al.. 2018. Glutamate and Glycine Binding to the NMDA Receptor.. Structure 26(7):1035-1043.e2 PMID: 29887499
- 5. Seljeset S et al.. 2024. Constitutive activity of ionotropic glutamate receptors via hydrophobic substitutions in the ligand-binding domain.. Structure 32(7):966-978.e6 PMID: 38677289
- 6. Kew JN et al.. 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology.. Psychopharmacology (Berl) 179(1):4-29 PMID: 15731895
- 7. Yuan H et al.. 2015. Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.. Mol Pharmacol 88(1):203-17 PMID: 25904555
- 8. Ibrahim HM et al.. 2000. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.. Am J Psychiatry 157(11):1811-23 PMID: 11058479
